We are live on ! Find out more
PAI

Palo Alto Investors Portfolio holdings

AUM $654M
1-Year Est. Return 77.8%
This Fund
S&P 500
This Quarter Est. Return
-4.25%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$1.15B
AUM Growth
-$146M
Cap. Flow
-$28.6M
Cap. Flow %
-2.49%
Top 10 Hldgs %
82.79%
Holding
35
New
–
Increased
1
Reduced
10
Closed
2

Top Buys

Rank Stock Value
1
EHTH icon
eHealth
EHTH
+$24.7K

Top Sells

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$10.7M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$6.23M
3
UTHR icon
United Therapeutics
UTHR
+$3.71M
4
ALKS icon
Alkermes
ALKS
+$2.02M
5
STAA icon
STAAR Surgical
STAA
+$1.96M

Sector Composition

Rank Sector Weight
1 Healthcare 98.64%
2 Financials 1.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MIRM icon
26
Mirum Pharmaceuticals
MIRM
$6.04B
$1.26M 0.11%
64,700
– –
ALIM
27
DELISTED
Alimera Sciences
ALIM
$1.1M 0.1%
200,919
– –
NVAX icon
28
Novavax
NVAX
$1.31B
$643K 0.06%
12,500
– –
ALDX icon
29
Aldeyra Therapeutics
ALDX
$91.7M
$642K 0.06%
160,800
– –
DNTH icon
30
Dianthus Therapeutics
DNTH
$6.29B
$519K 0.05%
27,019
– –
URGN icon
31
UroGen Pharma
URGN
$2.39B
$201K 0.02%
24,500
– –
TCMD icon
32
Tactile Systems Technology
TCMD
$555M
$198K 0.02%
27,100
– –
MRNS
33
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$152K 0.01%
31,330
– –
RIGL icon
34
Rigel Pharmaceuticals
RIGL
$782M
– –
-65,240
Closed -$1.95M
KLDO
35
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
– –
-309,692
Closed -$511K
1
2

Similar funds

AG
Alibaba Group Causeway Bay, Hong Kong $653M AUM 16.11% 1-Year Est. Return
BL
BWCP LP Dallas, Texas $656M AUM 41.58% 1-Year Est. Return
PIM
Parker Investment Management Menlo Park, California $659M AUM 52.52% 1-Year Est. Return
ACA
Apis Capital Advisors New York $648M AUM 302.67% 1-Year Est. Return
PCM
Primavera Capital Management George Town, Cayman Islands $648M AUM 6.1% 1-Year Est. Return
HCM
Huber Capital Management El Segundo, California $647M AUM 24.91% 1-Year Est. Return
ACM
Arosa Capital Management Miami Beach, Florida $660M AUM 210.26% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Palo Alto Investors's Q2 2022 Portfolio in Review

As of Q2 2022, Palo Alto Investors held 35 positions worth $1.15B, down 11% from $1.29B the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Palo Alto Investors's Q2 2022 filing shows 1 increased, 10 reduced and 2 closed positions. The largest sale was Acadia Pharmaceuticals, an estimated $10.7M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Financials.

  • Palo Alto Investors added most to eHealth in Q2 2022, an estimated $24.7K increase.
  • Palo Alto Investors's biggest Q2 2022 reduction was Acadia Pharmaceuticals, cutting an estimated $10.7M.
  • Palo Alto Investors fully exited Rigel Pharmaceuticals in Q2 2022, selling an estimated $1.95M.
  • Palo Alto Investors's ten largest holdings make up 83% of its $1.15B portfolio in Q2 2022.
  • Palo Alto Investors opened 0 new positions and closed 2 in Q2 2022.
  • Palo Alto Investors's portfolio value fell 11% quarter-over-quarter to $1.15B.

Based on Palo Alto Investors's 13F filing for Q2 2022, filed 15 Aug 2022.